We are pleased to announce today that we have established a strategic collaboration with the Medicines Discovery Catapult (MDC) to help NC3Rs-funded researchers to translate their scientific findings into industry-ready products and services. The collaboration provides an opportunity for the researchers to work with the MDC, accessing the Catapult’s industrial expertise, facilities and equipment. To complement these in-kind contributions, we have launched the ‘Technologies to Tools’ funding scheme, which will be available to NC3Rs-funded researchers working with the MDC. The scheme will support human-relevant in vitro models and technologies to cross the ‘3Rs valley of death’ that often exists between model development and the wider uptake needed to achieve the greatest 3Rs impacts.
Dr Anthony Holmes, NC3Rs Director of Science and Technology, said: ‘NC3Rs-funded research represents a very broad, diverse portfolio of technologically advanced, human-relevant approaches. I believe we’re only just scratching the surface of the potential for these technologies to drive a paradigm shift in the way the pharmaceutical industry develops and tests new drugs; one where decisions on whether to progress a potential therapeutic are based on data generated in human-relevant systems and not animal models. The collaboration with MDC presents a timely opportunity in maintaining the position of NC3Rs-funded research at the forefront of these endeavours.’
For more information about the Technologies to Tools Research Showcase, visit the Medicines Discovery Catapult website.
About the Medicines Discovery Catapult
The Medicines Discovery Catapult is a national centre of applied Research and Development expertise to promote and support innovative, fast-to-patient drug discovery in the UK through collaborative projects.